<i>FOXO3</i> longevity genotype mitigates the increased mortality risk in men with a cardiometabolic disease

Randi Chen; Brian J. Morris; Timothy A. Donlon; Kamal H. Masaki; D. Craig Willcox; Philip M.C. Davy; Richard C. Allsopp; Bradley J. Willcox

doi:doi:10.18632/aging.202175

← Back

Research Paper Volume 12, Issue 23 pp 23509—23524

FOXO3 longevity genotype mitigates the increased mortality risk in men with a cardiometabolic disease

Figure 2. Mortality risk expressed as hazard ratio, adjusted for age, BMI and glucose, for CMD subjects and subjects without a CMD according to whether they were carriers of the longevity-associated (G) allele of the FOXO3 SNP rs2802292 (TG/GG) or were homozygous for the major (T) allele (i.e., were TT). In men with CMD and the FOXO3 longevity genotype, mortality risk was reduced to normal (i.e., did not differ significantly from that of men without CMD).